th trials are successful, no third phase III trial will be conducted.
If only one of the two trials is successful and the other trial has a treatment effect that points in the same direction,
a third phase III trial will be conducted with a sample size of N3 = N3(ymin), which depends on an assumed minimal clinical relevant effect (ymin).
The third trial then has to be significant at level alpha
If only one of the two trials is successful and the treatment effect of the other points in opposite direction or
